Zelira Therapeutics (AU:ZLD) has released an update.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Zelira Therapeutics is gearing up to present its latest business advancements at the Automic Invest 2024 conference, highlighting its successful proprietary cannabinoid medications like HOPE® and ZENIVOL®. With a robust pipeline and strategic partnerships, Zelira is expanding its market presence in the US, Australia, and Germany, aiming for significant growth in the global cannabinoid-based medicine sector.
For further insights into AU:ZLD stock, check out TipRanks’ Stock Analysis page.